ACM Biosciences

ACM Biosciences is a Swiss biotechnology company specializing in the development of next-generation vaccines and therapeutics using its proprietary Artificial Cell Membrane (ACM) technology. The platform utilizes synthetic polymersomes, which are highly stable and tunable vesicles that mimic natural cell membranes to deliver antigens or drug payloads effectively. The company's lead program, ACM-001, is a protein-based COVID-19 vaccine that has entered clinical evaluation. Beyond human health, ACM Biosciences also applies its delivery technology to veterinary medicine and other infectious diseases. The company is a spin-off from ACM Polymers and is headquartered in the Basel biotech cluster.